M John Chapman
France
Review Article
Residual Microvascular Risk in Type 2 Diabetes in 2014: Is it Time for a Re-Think? A Perspective from the Residual Risk Reduction Initiative (R3i)
Author(s): Michel P Hermans, Jean-Charles Fruchart, Jean Davignon, Khalid Al-Rubeaan, Pierre Amarenco, Gerd Assmann, Philip Barter, John Betteridge, Eric Bruckert, M John Chapman, Ada Cuevas, Michel Farnier, Ele Ferrannini, Paola Fioretto, Jacques Genest, Henry N Ginsberg, Antonio M Gotto Jr, Dayi Hu, Takashi Kadowaki, Tatsuhiko Kodama, Michel Krempf, Yuji Matsuzawa, Jesús Millán Núñez-Cortés, Carlos Calvo Monfil, Hisao Ogawa, Jorge Plutzky, Daniel J Rader, Željko Reiner, Shaukat Sadikot, Raul D Santos, Evgeny Shlyakhto, Piyamitr Sritara, Rody Sy, Alan Tall, Chee-Eng Tan, Lale Tokgözoglu, Peter P Toth, Paul Valensi, Christoph Wanner, Alberto Zambon, JunRen Zhu and Paul ZimmetMichel P Hermans, Jean-Charles Fruchart, Jean Davignon, Khalid Al-Rubeaan, Pierre Amarenco, Gerd Assmann, Philip Barter, John Betteridge, Eric Bruckert, M John Chapman, Ada Cuevas, Michel Farnier, Ele Ferrannini, Paola Fioretto, Jacques Genest, Henry N Ginsberg, Antonio M Gotto Jr, Dayi Hu, Takashi Kadowaki, Tatsuhiko Kodama, Michel Krempf, Yuji Matsuzawa, Jesús Millán Núñez-Cortés, Carlos Calvo Monfil, Hisao Ogawa, Jorge Plutzky, Daniel J Rader, Željko Reiner, Shaukat Sadikot, Raul D Santos, Evgeny Shlyakhto, Piyamitr Sritara, Rody Sy, Alan Tall, Chee-Eng Tan, Lale Tokgözoglu, Peter P Toth, Paul Valensi, Christoph Wanner, Alberto Zambon, JunRen Zhu and Paul Zimmet
Microvascular complications associated with type 2 diabetes, including diabetic retinopathy, nephropathy and neuropathy, account for much of the societal burden of diabetes. Even with effective multifactorial intervention, targeting glycemia, blood pressure and lowdensity lipoprotein cholesterol, in addition to lifestyle intervention, a high residual microvascular risk persists. The Residual Risk Reduction Initiative (R3i) highlights two key priorities for reducing this residual risk. First, there should be optimal management of cardiometabolic risk factors, including atherogenic dyslipidemia, elevated triglycerides and low plasma high-density lipoprotein cholesterol, to improve lipid goal attainment. Second, consistent evidence from two major trials may merit consideration of adjunctive fenofibrate therapy to slow progression of diabetic retinopathy in type 2 diabetes patients with p.. View More»
